Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia

A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease

(2017) Wai Kin D. Ko et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias

(2017) Silvia Cerri et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Non-motor features of Parkinson disease

(2017) Anthony H.V. Schapira et al.   NATURE REVIEWS NEUROSCIENCE

Purinergic Signalling: Therapeutic Developments

(2017) Geoffrey Burnstock   Frontiers in Pharmacology

Antidyskinetic effect of A2Aand 5HT1A/1Breceptor ligands in two animal models of Parkinson's disease

(2016) Annalisa Pinna et al.   MOVEMENT DISORDERS

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms

(2016) Veronica Ghiglieri et al.   NEUROBIOLOGY OF DISEASE

Purinergic signalling in brain ischemia

(2016) Felicita Pedata et al.   NEUROPHARMACOLOGY

Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson’s disease?

(2015) Erwan Bezard et al.   BRAIN

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

(2015) Per Svenningsson et al.   BRAIN

Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulatesl-DOPA-induced rotational behavior in a rodent model of Parkinson's disease

(2015) Marie-Therese Fuzzati-Armentero et al.   JOURNAL OF NEUROCHEMISTRY

New treatments for levodopa-induced motor complications

(2015) Olivier Rascol et al.   MOVEMENT DISORDERS

New insight into the therapeutic role of the serotonergic system in Parkinson's disease

(2015) Yukihiro Ohno et al.   PROGRESS IN NEUROBIOLOGY

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

(2015) Matthieu F. Bastide et al.   PROGRESS IN NEUROBIOLOGY

Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation

(2015) Nicola Simola et al.   PSYCHOPHARMACOLOGY

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease

(2015) Robert A. Hauser et al.   JAMA Neurology

Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

(2014) Annalisa Pinna   CNS DRUGS

l-DOPA disrupts adenosine A2A–cannabinoid CB1–dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies

(2014) Annalisa Pinna et al.   EXPERIMENTAL NEUROLOGY

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients

(2014) Marios Politis et al.   JOURNAL OF CLINICAL INVESTIGATION

Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions

(2014) Rolf Heumann et al.   JOURNAL OF NEUROCHEMISTRY

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial

(2014) Robert A Hauser et al.   LANCET NEUROLOGY

Advances in non-dopaminergic treatments for Parkinson's disease

(2014) Sandy Stayte et al.   Frontiers in Neuroscience

Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations

(2014) Manolo Carta et al.   Frontiers in Neurology

A2A receptor antagonists do not induce dyskinesias in drug-naive or l-dopa sensitized rats

(2013) N. Jones et al.   BRAIN RESEARCH BULLETIN

Istradefylline: First Global Approval

(2013) Rosselle Dungo et al.   DRUGS

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

(2013) Stewart A. Factor et al.   MOVEMENT DISORDERS

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia

(2013) Erwan Bezard et al.   MOVEMENT DISORDERS

Serotonergic nerve fibers in l-DOPA-derived dopamine release and dyskinesia

(2013) N. Nevalainen et al.   NEUROSCIENCE

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia

(2013) Erwan Bézard et al.   NEUROSCIENCE RESEARCH

A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists

(2013) Annalisa Pinna et al.   NEUROTOXICITY RESEARCH

Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System

(2012) Patrizia Popoli et al.   CNS & Neurological Disorders-Drug Targets

GPCR Heteromers and their Allosteric Receptor-Receptor Interactions

(2012) K. Fuxe et al.   CURRENT MEDICINAL CHEMISTRY

A2AReceptor Antagonism and Dyskinesia in Parkinson’s Disease

(2012) Micaela Morelli et al.   Parkinsons Disease

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

(2011) Susan Duty et al.   BRITISH JOURNAL OF PHARMACOLOGY

Adenosine A2A receptor in the monkey basal ganglia: Ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum

(2011) James W. Bogenpohl et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Arousal Effect of Caffeine Depends on Adenosine A2A Receptors in the Shell of the Nucleus Accumbens

(2011) M. Lazarus et al.   JOURNAL OF NEUROSCIENCE

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia

(2011) M. Carta et al.   NEUROSCIENCE

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update

(2011) B. B. Fredholm et al.   PHARMACOLOGICAL REVIEWS

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

(2011) Marie Therese Armentero et al.   PHARMACOLOGY & THERAPEUTICS

The serotonergic system in Parkinson's disease

(2011) Philippe Huot et al.   PROGRESS IN NEUROBIOLOGY

Adenosine-cannabinoid receptor interactions. Implications for striatal function

(2010) Sergi Ferré et al.   BRITISH JOURNAL OF PHARMACOLOGY

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

(2010) Robert A. Hodgson et al.   EXPERIMENTAL NEUROLOGY

Presynaptic control of serotonin on striatal dopamine function

(2010) Sylvia Navailles et al.   PSYCHOPHARMACOLOGY

Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants

(2010) M. Politis et al.   Science Translational Medicine

Adenosine signaling and function in glial cells

(2009) D Boison et al.   CELL DEATH AND DIFFERENTIATION

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

(2009) R. A. Hodgson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The scientific and clinical basis for the treatment of Parkinson disease (2009)

(2009) C. W. Olanow et al.   NEUROLOGY

A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug

(2009) Annalisa Pinna et al.   NEUROPHARMACOLOGY

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

(2008) A. Munoz et al.   BRAIN

Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions

(2008) N. Simola et al.   CURRENT PHARMACEUTICAL DESIGN

Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors

(2008) Jiang-Fan Chen et al.   CURRENT PHARMACEUTICAL DESIGN

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism

(2008) John et al.   Frontiers in Bioscience-Landmark

Detection of heteromerization of more than two proteins by sequential BRET-FRET

(2008) Paulina Carriba et al.   NATURE METHODS

Molecular mechanisms of L-DOPA-induced dyskinesia

(2008) Peter Jenner   NATURE REVIEWS NEUROSCIENCE

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY

The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates

(2008) Geoffrey B. Varty et al.   PSYCHOPHARMACOLOGY

Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D1 or D2 dopamine receptor agonists

(2008) Nicola Simola et al.   SYNAPSE

Detection of Heteromers Formed by Cannabinoid CB1, Dopamine D2, and Adenosine A2AG-Protein-Coupled Receptors by Combining Bimolecular Fluorescence Complementation and Bioluminescence Energy Transfer

(2008) Gemma Navarro et al.   TheScientificWorldJOURNAL

The A3 adenosine receptor: An enigmatic player in cell biology

(2007) Stefania Gessi et al.   PHARMACOLOGY & THERAPEUTICS